JAMA|2025|Anderer S|1 citation
PMID: 40314963
14102 studies
BACKGROUND: Substantial weight reduction is often associated with loss of muscle mass. Tirzepatide has been associated with significant reductions in body weight in type 2 diabetes trials and a beneficial effect on body fat distribution in the SURPAS…
The prevalence of prediabetes has more than doubled over the past two decades. Although hormones associated with the menstrual cycle may offer some protection against diabetes by enhancing insulin sensitivity and suppressing gluconeogenesis, the prev…
AIM: To assess the association of tirzepatide use with a 10-year predicted risk of type 2 diabetes (T2D) among Chinese participants with obesity or overweight from the SURMOUNT-CN trial. MATERIALS AND METHODS: In this post hoc analysis, the QDiabetes…
INTRODUCTION: Tirzepatide is one of the commonly used combined glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) agonists for weight loss in recent years. There are significant advantages of these medications for…
Obstructive sleep apnea (OSA) is a very common sleep disorder and is usually a chronic disease. Indications for treatment depend on the severity of the nocturnal breathing disorder; the specific symptoms, such as daytime sleepiness; and the comorbidi…
Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide, with limited therapeutic options targeting both cardiac function and metabolic comorbidities. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP…
The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD…
AIMS: Tirzepatide reduced weight significantly more than placebo in adults with obesity/overweight who had already achieved ≥5% weight reduction with a 12-week intensive lifestyle intervention (randomized population) in SURMOUNT-3, a phase 3, 72-week…
OBJECTIVE: Aim: To examine potential protective effect of Tirzepatide against obesity-induced metabolic dysfunction and hepatic inflammatory and apoptotic responses. PATIENTS AND METHODS: Materials and Methods: A total of 28 adult male Sprague-Dawley…
BACKGROUND: Tirzepatide-a dual GIP/GLP-1 receptor agonist-exerts pleiotropic effects on cardiometabolic health. OBJECTIVES: The authors sought to investigate the efficacy of tirzepatide in improving different cardiometabolic risk factors across indiv…
Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown promise in improving metabolic and cardiovascular profiles in patients with obesity. However, its potential ben…
AIMS/HYPOTHESIS: In type 1 diabetes, the counterregulatory glucagon response to low plasma glucose is impaired. The resulting increased risk of hypoglycaemia necessitates novel strategies to ameliorate alpha cell impairment. Here, we aimed to establi…
Diabetes mellitus is an increasingly common long-term metabolic disease. There are many treatment options available to manage type 2 diabetes and reduce the risk of associated long-term microvascular and macrovascular complications. The management of…
AIMS: Suicide is a global public health concern, accounting for nearly 700,000 deaths annually. Although well-established risk factors, including mental health disorders, are widely recognized, emerging concerns have surfaced regarding a potential as…